SanegeneBio

📍 Woburn, United States🗓 Founded 2021👥 28 employees💰 Last funded 2021
Biotechnology Research🌐 sanegenebio.com
Website LinkedIn
Sanegene Bio is a clinical-stage, fully integrated biotechnology company backed by a syndicate of private equity investors. We are focused on discovering and developing best-in-class genetic medicines for obesity, cardiometabolic, and autoimmune diseases using RNA interference (RNAi) technology. Founded in 2021 by industry veterans with deep RNAi expertise, SanegeneBio is headquartered in Boston, with R&D operations in both the U.S. and China. Our proprietary technology platform, LEAD™ (Ligand and Enhancer Assisted Delivery), enables tissue-specific silencing of disease-driving genes in the liver, adipose tissue, muscle, and immune cells—achieved through safe, infrequent subcutaneous dosing. Sanegene Bio is committed to advancing transformative RNAi therapies that address global unmet medical needs.
1
Total investors
1
Early stage
0
Mid stage
0
Late stage
2021
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
China
1
Frequently asked questions
Who invested in SanegeneBio?
SanegeneBio has 1 investors on record on gritt.io, including 1 early-stage backers.
When did SanegeneBio last raise funding?
The most recent investment in SanegeneBio recorded on gritt.io was in 2021.
When was SanegeneBio founded?
SanegeneBio was founded in 2021.
What industry is SanegeneBio in?
SanegeneBio operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is SanegeneBio based?
SanegeneBio is headquartered in Woburn, United States.